Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sex-Specific Responses in the Early Stages of Diet-Induced Cardiovascular-Kidney-Metabolic Syndrome.

American journal of physiology. Heart and circulatory physiology·2026

Same author

N- and O‑Prenylated Quinolones: Syntheses and <i>In Vitro</i> and <i>In Vivo</i> Antischistosomal Evaluation.

ACS medicinal chemistry letters·2026

Same author

Natural Products Inspired Scaffold Diversification Leads to Unnatural Molecular Warhead and Covalent Strategy to Modulating Protein Function through Electrophilic Bromine Transfer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

<i>N</i>‑Myristoyltransferase Inhibitors as a Potential Starting Point for the Development of Antischistosomal Agents.

ACS medicinal chemistry letters·2026

Same author

Correction to "Novel Scaffold Unlocks Potent Cross-Peptidase and Cross-Species Inhibitors as Promising Antimalarial Agents".

Journal of medicinal chemistry·2026

Same author

Broad-Spectrum Anti-Infective Activity of Natural Compounds Pyrrolomycins, Marinopyrroles, and Their Analogs.

Pathogens (Basel, Switzerland)·2026

Search research articles

Related Experiment Video

Updated: Jun 10, 2025

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Published on: August 16, 2011

Single-Dose Drug Development Candidate for Schistosomiasis.

Derek A Leas¹, Jennifer Keiser^2,3, Susan A Charman⁴

¹College of Pharmacy, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, Nebraska 986125, United States.

ACS Infectious Diseases

|October 18, 2024

Summary

This summary is machine-generated.

Researchers developed AR102, a novel antischistosomal drug candidate. This compound offers potent activity, improved stability, and a better safety profile by modifying aryl hydantoins to eliminate antiandrogenic side effects.

Keywords:

antiandrogenic antischistosomal aryl hydantoin structure−activity relationship

More Related Videos

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Published on: January 14, 2018

Related Experiment Videos

Last Updated: Jun 10, 2025

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Cercarial Transformation and in vitro Cultivation of Schistosoma mansoni Schistosomules

Published on: August 16, 2011

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Mass Isolation and In Vitro Cultivation of Intramolluscan Stages of the Human Blood Fluke Schistosoma Mansoni

Published on: January 14, 2018

Area of Science:

Medicinal Chemistry
Parasitology
Drug Discovery

Background:

Aryl hydantoins showed early promise as antischistosomal agents.
Early compounds like Ro 13-3978 exhibited undesirable antiandrogenic side effects due to structural similarities with nilutamide.

Purpose of the Study:

To optimize the aryl hydantoin chemotype for antischistosomal activity.
To eliminate antiandrogenic side effects and enhance metabolic stability.
To discover a safe and effective single-dose drug candidate against schistosomes.

Main Methods:

Structural modification of Ro 13-3978 by replacing the aryl trifluoromethyl group with difluoroethyl.
Substitution of hydrogen atoms in the gem-dimethyl substructure with deuterium to improve metabolic stability.
Preclinical evaluation of the novel compound AR102 for efficacy, pharmacokinetics, and safety.

Main Results:

The structural modifications successfully abolished antiandrogenic effects.
AR102 demonstrated potent, selective, and broad-spectrum activity against schistosomes.
The drug candidate exhibited a long pharmacokinetic half-life and an acceptable safety profile in preclinical studies.

Conclusions:

AR102 represents a significant advancement in antischistosomal drug development.
The optimized aryl hydantoin derivative offers a promising solution for treating schistosomiasis.
This work validates a strategy for developing safer and more effective antiparasitic agents.